[MOL] New Assay Improves the Specificity of PSA Testing [01267] Medicine On Line

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] New Assay Improves the Specificity of PSA Testing

Title: New Assay Improves the Specificity of PSA Testing

Good Day My Friends,

This article may have been posted previously. I believe it may be a current article and hope it will benefit those that are seeking more information about PSA and cancer.  Have a great day.

God Bless You,
marty auslander

Site Map   Your Account   Support   About Us
Offerings:  Medscape.com   Charts   Mobile   Logician   CBSHealthwatch
Reuters Medical News - for the Professional
New Assay Improves the Specificity of PSA Testing

WESTPORT, CT (Reuters Health) Nov 27 - For men with moderately elevated prostate-specific antigen levels, the use of an assay for serum PSA alpha-1 protease inhibitor has the potential to improve the specificity of PSA testing, according to Finnish researchers. 

Dr. Patrik Finne, from Helsinki University, and colleagues from there and elsewhere in Finland evaluated serum samples from 304 patients. In this population, 78 patients had prostate cancer and 226 did not, but all had serum PSA of 4 to 10 mcg/L. The researchers used a commercial kit to measure total PSA and free PSA and used an immunoassay of their own design to measure PSA alpha-1 protease inhibitor. 

According to their report in the December issue of the Journal of Urology, in patients with prostate cancer, the proportion of serum PSA alpha-1 protease inhibitor of total PSA was lower than it was in controls (0.9% versus 1.6%). On logistic regression, PSA alpha-1 protease inhibitor independently discriminated between patients who had prostate cancer and those who did not. 

The investigators also noted that the specificity of PSA testing was improved when the probability of prostate cancer was calculated by logistic regression of both PSA alpha-1 protease inhibitor and free PSA, versus the use of total PSA or free PSA alone. At a sensitivity of 95%, consideration of the combination of PSA alpha-1 protease inhibitor and free PSA eliminated 41% of false-positive results caused by benign conditions. 

Dr. Finne and colleagues acknowledge that the new assay is more complicated than the conventional assay and more expensive by 30% to 40%. They conclude, "Whether this cost is considered justified depends on how the unnecessary biopsies and patient worry are valued." 

J Urol 2000;164:1956-1960. 

Reuters Copyright © 2000 Reuters Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Family Medicine


Internal Medicine

Med Students


Today on Medscape



Today's News

Click Here for www.lillydiabetes.com

Site Map   Your Account   Support   About Us

Medscape Search Options
Select a database to search, enter a search term, then click ďgo.Ē    Advanced Search Forms

All material on this website is protected by copyright. Copyright © 1994-2000 by Medscape Inc. All rights reserved. This website also contains material copyrighted by 3rd parties. Medscape requires 3.x browsers or better from Netscape or Microsoft.